Loss of PTEN expression as a prognostic marker for tongue cancer

被引:105
作者
Lee, JI
Soria, JC
Hassan, KA
El-Naggar, AK
Tang, XM
Liu, DD
Hong, WK
Mao, L
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Mol Biol Lab, Houston, TX 77030 USA
[2] Baylor Coll Med, Bobby R Alford Dept Otorhinolaryngol & Commun Sci, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
D O I
10.1001/archotol.127.12.1441
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Abnormalities of PTEN, a candidate tumor suppressor gene located at 10q23.3, play an important role in the tumorigenesis of multiple tumor types. Objectives: To investigate the expression of PTEN and its clinical implication in squamous cell carcinoma of the tongue. Design: Retrospective analysis of PTEN protein expression in archived primary oral tongue tumor samples. Setting: Academic center, Patients and Methods: PTEN expression was determined by immunohistochemical analysis in tissue samples from 41 patients with stage II, III, and IV squamous cell carcinoma of the tongue. All the patients underwent curative surgical treatment with a median follow-up of 81 months. The Kaplan-Meier method was used for survival analysis. Multivariate analysis was performed according to the Cox proportional hazards model. Results: Lack of staining for PTEN was demonstrated in 12 (29%) of the 41 tumors. Patients whose tumors lacked PTEN expression had a significantly shorter overall survival time (P=.03) and event-free survival time (P=.01) than those patients with positive PTEN expression. Multivariate regression analysis demonstrated that PTEN expression is an independent predictor of poor outcome when compared with tumor stage and nodal status. Conclusions: Although genetic alterations of the PTEN gene are rare in head and neck squamous cell carcinoma, loss of PTEN is not an uncommon event in squamous cell carcinoma of the tongue. Lack of PTEN expression may be an independent prognostic indicator for clinical outcome in patients with this tumor type.
引用
收藏
页码:1441 / 1445
页数:5
相关论文
共 22 条
[11]   5' CPG ISLAND METHYLATION IS ASSOCIATED WITH TRANSCRIPTIONAL SILENCING OF THE TUMOR-SUPPRESSOR P16/CDKN2/MTS1 IN HUMAN CANCERS [J].
MERLO, A ;
HERMAN, JG ;
MAO, L ;
LEE, DJ ;
GABRIELSON, E ;
BURGER, PC ;
BAYLIN, SB ;
SIDRANSKY, D .
NATURE MEDICINE, 1995, 1 (07) :686-692
[12]   Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [J].
Mutter, GL ;
Lin, MC ;
Fitzgerald, JT ;
Kum, JB ;
Baak, JPA ;
Lees, JA ;
Weng, LP ;
Eng, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) :924-931
[13]  
Okami K, 1998, CANCER RES, V58, P509
[14]   Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast [J].
Perren, A ;
Weng, LP ;
Boag, AH ;
Ziebold, U ;
Thakore, K ;
Dahia, PLM ;
Komminoth, P ;
Lees, JA ;
Mulligan, LM ;
Mutter, GL ;
Eng, C .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1253-1260
[15]  
Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO
[16]  
2-S
[17]  
SHAH JP, 1996, HEAD NECK SURG, P189
[18]  
Shao XY, 1998, INT J CANCER, V77, P684, DOI 10.1002/(SICI)1097-0215(19980831)77:5<684::AID-IJC4>3.3.CO
[19]  
2-8
[20]   Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J].
Steck, PA ;
Pershouse, MA ;
Jasser, SA ;
Yung, WKA ;
Lin, H ;
Ligon, AH ;
Langford, LA ;
Baumgard, ML ;
Hattier, T ;
Davis, T ;
Frye, C ;
Hu, R ;
Swedlund, B ;
Teng, DHF ;
Tavtigian, SV .
NATURE GENETICS, 1997, 15 (04) :356-362